Protecting the Public from Unapproved, Diverted, or Counterfeit Drugs presenting Overdose Risks
To enhance the security of the U.S. drug supply chain, FDA is:
- Preventing and reducing counterfeit and illegal online sales
- Instituting enhanced targeting and screening methods at International Mail Facilities, Express Couriers, and Ports of Entry
- Taking compliance and enforcement actions against unapproved, diverted, or counterfeit drug products
United States Government Partners
- Drug Enforcement Administration (DEA)
- Customs and Border Protection (CPB)
FDA Activities
- FDA Moves Forward with Mail-back Envelopes for Opioid Analgesics Dispensed in Outpatient Settings
- Examining Ingredient Substitution in the Opioid Pharmaceutical Supply Chain: Findings from CDER’s Product Survey
- Online Opioid Summit
- FDA takes action against websites marketing unapproved opioids